Balancing act for Treg immunotherapy

Abstract

In this issue of Blood,Gaidot and colleagues demonstrate effective suppression of graft-versus-host disease (GVHD) by recipient-specific regulatory T cells without compromising immunity after hematopoietic stem cell transplantation (HCT).1 Should these findings push the transplant community toward widespread use of Treg immunotherapy to prevent GVHD?